Weekly round-up: Optimum celebrates innovation from industry awards to breakthrough treatments
Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata
Alys Pharmaceuticals announced that the first patient has been dosed in its Phase IIa trial of ALY-101 in patients suffering from Alopecia Areata. ALY-101 is formulated as an intradermal injectable and its unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications.
Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies
Novo Holdings announced its participation in a €23 million Series A round for Tribune Therapeutics. The round was led by new investor LifeArc Ventures and included Novo Holdings, HealthCap, Innovestor’s Life Science Fund and Inven2, as well as new Series A investors Industrifonden and Investinor.
Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer
Asgard Therapeutics announced the appointment of experienced immunology drug development specialist Shane Olwill as Chief Development Officer (CDO). Shane, who joins Asgard from Pieris Pharmaceuticals, will lead IND-enabling studies and clinical trials planning for Asgard’s lead asset AT-108.
Gergely Sved appointed CEO of Ellab
Ellab, the leading provider of validation, monitoring, and calibration services and solutions, announced that it has appointed Gergely Sved as its new Chief Executive Officer. Mr Sved will formally join the company in June, with Chief Financial Officer Andreas Morthorst acting as interim CEO.
Poolbeg to Participate in Key Conferences in March and April 2025
Poolbeg Pharma announced that CEO, Jeremy Skillington, will present at the Master Investor Show (29th March) and BioTrinity (2nd April), and participate in a panel discussion at LSX World Congress (30th April).
Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
Heidelberg Pharma announced that it will be presenting its latest ADC research results and development of its Exatecan-based ADC technology platform at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois, USA, from 25 to 30 April.
Optimum TV
Pneumococcal bacteria are the third biggest cause of death by bacterial infections globally – and while effective vaccines exist, they are expensive to make and only cover certain serotypes. Watch as Neil Murray explains how UK-biotech ReNewVax is developing a universal vaccine to protect against all serotypes of Streptococcus pneumoniae, which can cause pneumonia, certain forms of meningitis, and sepsis. See the latest episode of Optimum TV below.
Optimum’s hot topic
Industry events
🌟 One Nucleus Awards
What a brilliant night at the 2nd Annual One Nucleus Awards in London last night! Our very own Zoe Bolt presented the Best Performing Creative Investor award to Deep Science Ventures and our client Resolution Therapeutics was shortlisted for the Best Performing Therapeutic Discovery Company of the Year.
👥Anglonordic
Its less than a week to go until the 21st Anglonordic Life Science Conference. Optimum has programmed the agenda and what a stellar line up of life science leaders it is. We are looking forward to seeing everyone at the conference next week! Today is the final day to book your spot so, register with Optimum’s 20% F&F discount – OPTIMUM20 here: https://www.anglonordiclifescience.com/
🤝 BioEquity Europe
Optimum is proud to sponsor the networking breakfast at the 25th anniversary edition of BioCentury’s BioEquity Europe! A premier event uniting VCs, biotech, and pharma leaders. This year’s agenda explores what’s next for European biotechs as they navigate Asian asset sourcing, globalisation challenges, and geopolitical tensions.
Reach out to connect with our team in Bruges, Belgium in May!
Sector Moves
Keep up to date with the latest industry moves here.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
